Status:
COMPLETED
Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction
Lead Sponsor:
Baskent University
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
45-65 years
Phase:
PHASE4
Brief Summary
The present study aimed to evaluate the effect of rosiglitazone treatment on cardiac function compared with metformin
Detailed Description
Large scale clinical trials have reported fluid retention and increase in plasma volume (6% to 7%) with glitazone therapy, with an increased incidence of peripheral edema occuring in 2% to 5% patients...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus treated with oral hypoglycemic agents or diet only
- Without any symptom or finding of heart failure
- Normal liver enzymes and renal functions
Exclusion
- Any known coronary artery disease, congestive hearth failure, renal disease or liver disease
- Any treatment for heart failure or diuretics for any reasons.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00300911
Start Date
December 1 2005
Last Update
March 10 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baskent University Ankara Hospital
Ankara, Turkey (Türkiye), 06490